Lycorine ( Lycoris radiata )—a unique natural medicine on breast cancer
Journal of Cellular and Molecular Medicine · 2024-08 · 28 (16)
DOI: 10.1111/jcmm.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 22.08.2024. Verfasst von Qinbing Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center for Medicine, Ministry of Education, Harbin University of Commerce, Harbin, China. Hauptthemen laut MEDLINE: Phenanthridines, Amaryllidaceae Alkaloids, Breast Neoplasms, Lycoris. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Key Research and Development Program of Heilongjiang Province, Jinghu Program of Harbin University of Commerce, the Young Innovative Talents Training Program of Harbin University of Commerce.
Abstract (Originalsprache)
Breast cancer (BC) is one of the most common types of cancer among women worldwide. Lycorine ( Lycoris radiata ), a small molecule derived from the traditional Chinese herb Amaryllidaceae plants, has appeared potential effect on inhibiting the growth of cancer cells and inducing apoptosis in various types of cancer with minor side effects. To discuss the therapeutic effects and molecular mechanisms of lycorine on BC established by lycorine‐treated S180 tumour‐bearing mice in vivo. Furthermore, both the mitotic and microtubule assembly dynamics genes were performed by qPCR assays, and the protein expression associated with mitotic arrest was investigated by western blot. Lycorine was demonstrated to reduce sarcoma growth of S180 tumour‐bearing mice and inhibit the proliferation of MCF‐7 cells in concentration‐dependent manner. Moreover, lycorine induced M phase cell cycle arrest via interfering with the mitotic apparatus regulated the expression of 20 genes and 15 proteins in cell cycle progression. Furthermore, this study confirmed that the potential effect of lycorine on BC might be mediated by cell cycle arrest in M phase for the first time. These results would be the consequence of exploitation of lycorine as a potential drug for BC therapy, however further preclinical and clinical studies are still needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Research Center for Medicine, Ministry of Education, Harbin University of Commerce, Harbin, China.
- School of Food Engineering, Harbin University of Commerce, Harbin, China.
- Department of Medical Imaging, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
ORCID-Profile: Zheng Qi
Förderung
- the Key Research and Development Program of Heilongjiang Province
- Jinghu Program of Harbin University of Commerce
- the Young Innovative Talents Training Program of Harbin University of Commerce
- National Natural Science Foundation of China
Zitieren
APA
Xue, Q., Wang, B., Feng, J., Li, C., Yu, M., Zhao, Y., & Qi, Z. (2024). Lycorine ( Lycoris radiata )—a unique natural medicine on breast cancer. Journal of Cellular and Molecular Medicine, 28(16). https://doi.org/10.1111/jcmm.70032
Vancouver
Xue Q, Wang B, Feng J, Li C, Yu M, Zhao Y, et al. Lycorine ( Lycoris radiata )—a unique natural medicine on breast cancer. Journal of Cellular and Molecular Medicine. 2024;28(16). doi:10.1111/jcmm.70032
BibTeX
@article{Xue2024,
author = {Xue, Qinbing and Wang, Bing and Feng, Jie and Li, Chaoyu and Yu, Miao and Zhao, Yan and Qi, Zheng},
title = {Lycorine ( Lycoris radiata )—a unique natural medicine on breast cancer},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {16},
doi = {10.1111/jcmm.70032}
}
EUVIMED